Trial Parameters
Brief Summary
The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single doses of KLA478 in healthy volunteers；
Eligibility Criteria
Inclusion Criteria: 1. Sign the informed consent form 2. Health participants (Age: 18\~45 years); 3. Body Weight: Male≥50.0kg, Female≥45.0kg; 19 ≤BMI≤ 28.0kg/m2; 4. Clinical examination normal, or abnormal with no clinical significance； 5. Agreed to use contraception for 3-6 months. Exclusion Criteria: 1. Allergy or Drug hypersensitivity; 2. Clinically significant Medical History； 3. Subjects with difficult venous blood collection/intolerance to venipuncture, or with a history of needle phobia/blood phobia； 4. Assess injection site abnormalities； 5. History of drugs that may interact with pramipexole within 1 month； 6. History of any Medication within 2 weeks； 7. Massive blood loss (\> 200 mL) in the past 3 months； 8. History of any surgery within 3 months, or plan to undergo surgery during the trial； 9. History of any clinical study within 90 days； 10. History of any vaccine within 1 month，or Plan to get vaccinated during the trial period； 11. systolic blood pressure decreased ≥20 mmH